NASDAQ · Health care

Ani Pharmaceuticals Inc (ANIP)

Ani Pharmaceuticals Inc brought in $1B of revenue over the twelve months to September 30, 2026, up 25.9% from a year earlier. Net income was $116.8M, a net margin of 11.2%. Operating cash flow minus capital spending left $171.4M of free cash flow in fiscal 2025. At September 30, 2026 it held $420.8M in cash against $297.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.

Watch ANIP in 60 seconds

Price

$67.79

+0.56% on the day · November 9, 2026

52-week range $67.14 to $90.73

Market cap

$1.6B

Revenue (last 12 months)

$1B

+25.9% year on year

Net margin

11.2%

P/E

20.4

on FY2025 diluted EPS

Key facts about Ani Pharmaceuticals Inc

Net worth: Ani Pharmaceuticals Inc has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $637.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $883.4M (+43.8% year on year), with net income of $78.3M. Over the 12 months to September 30, 2026: revenue $1B, net income $116.8M.
Cash flow: In fiscal 2025 operations brought in $185.2M of cash; after $13.8M of capital spending, free cash flow was $171.4M.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: Ani Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Ani Pharmaceuticals Inc does

Ani Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ANIP.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$883.4M	$111.1M	$78.3M	$3.32	$171.4M
2024	$614.4M	$584K	-$18.5M	-$1.04	$47.8M
2023	$486.8M	$47M	$18.8M	$0.85	$110.1M
2022	$316.4M	-$35.3M	-$47.9M	-$3.05	-$40.1M
2021	$216.1M	-$39.8M	-$42.6M	-$3.40	$765K
2020	$208.5M	-$16M	-$22.5M	-$1.88	$9.1M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around January 11, 2027.

Estimated from its filing rhythm: 52 weeks after its report of January 12, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where ANIP ranks in Health care

Revenue$883.4M

#161 of 751 in Health care · Top 21%

Revenue growth+43.8%

#105 of 532 in Health care · Top 20%

Net margin8.9%

#121 of 544 in Health care · Top 22%

Free cash flow margin19.4%

#62 of 490 in Health care · Top 12%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $1.2M in cash dividends, 1% of its net income.

Fiscal year	Per share	Paid out	Of profit
2025	n/a	$1.2M	1%
2024	n/a	$1.6M	n/a
2023	n/a	$1.6M	9%
2022	n/a	$1.6M	n/a
2021	n/a	$190K	n/a
2020	n/a	$0	n/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Ani Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 5, 2026
Material agreement 8-K
November 5, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 28% to $290.8M versus the same quarter last year; diluted EPS $1.51 versus $1.13.
November 5, 2026
Quarterly results 8-K
August 24, 2026
Executive or director change 8-K
August 7, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 26% to $266M versus the same quarter last year; diluted EPS $1.05 versus $0.36.
August 7, 2026
Quarterly results 8-K
July 27, 2026
Passive stake changed SCHEDULE 13G/A
July 17, 2026
Employee stock plan registration S-8
May 21, 2026
Executive or director change 8-K
May 13, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on October 30, 2026. Insider transactions on SEC

What is ANIP worth? A DCF from its reported cash flow

Insider trades

What the people running Ani Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$2M

last 90 days

Net sold

27,250

$2M

Date	Insider	What	Shares	Price	Value	Filing
October 29, 2026	Carey Stephen P.SVP & CFO	Soldpre-planned (10b5-1)	2,850	$72.87	$207.7K	Form 4
October 15, 2026	Lalwani NikhilPRESIDENT & CEO, Director	Soldpre-planned (10b5-1)	5,400	$71.89	$388.2K	Form 4
October 13, 2026	Cook MeredithSR. VP, GENERAL COUNSEL & SEC.	Soldpre-planned (10b5-1)	500	$73.59	$36.8K	Form 4
September 29, 2026	Carey Stephen P.SVP & CFO	Soldpre-planned (10b5-1)	2,850	$73.00	$208.1K	Form 4
September 15, 2026	Lalwani NikhilPRESIDENT & CEO, Director	Soldpre-planned (10b5-1)	5,400	$71.00	$383.4K	Form 4
September 14, 2026	Cook MeredithSR. VP, GENERAL COUNSEL & SEC.	Soldpre-planned (10b5-1)	500	$70.79	$35.4K	Form 4
September 11, 2026	Thoma JeanneDirector	Soldpre-planned (10b5-1)	1,000	$71.53	$71.5K	Form 4
August 31, 2026	Carey Stephen P.SVP & CFO	Soldpre-planned (10b5-1)	2,850	$72.80	$207.5K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ANIP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: The Vanguard Group 0% (March 26, 2026); Millennium Management LLC 0.3% (November 13, 2025); Robert E. Brown, Jr. 4.8% (August 22, 2025); Rubric Capital Management LP 0.27% (November 13, 2024); Muthusamy Shanmugam 4.8% (January 17, 2024).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

16 insiders reported holding 1,343,264 shares in total, about $91.1M at the last price.

Holder	Shares	As of
Lalwani NikhilPRESIDENT & CEO, Director	333,689	October 15, 2026
Gassert ChadSVP - CORP. DEV. & STRATEGY	233,406158,490 held indirectly	February 28, 2026
Carey Stephen P.SVP & CFO	166,143	October 29, 2026
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS, Director	101,056	February 26, 2026
Mutz ChristopherHEAD OF RARE DISEASE	91,309	March 13, 2026
Gutwerg OriSVP, GENERICS	75,534	August 10, 2026
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.	73,424	October 13, 2026
Davis KristaSVP, CHIEF HR OFFICER	51,946	March 9, 2026
Haughey ThomasDirector	38,878	June 8, 2026
Walsh Patrick DDirector	38,432	May 13, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ANIP

What does Ani Pharmaceuticals Inc do?

Ani Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as ANIP. Its shares trade on NASDAQ under the ticker ANIP.

What is Ani Pharmaceuticals Inc's net worth?

Ani Pharmaceuticals Inc has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $637.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Ani Pharmaceuticals Inc profitable?

Yes. Over the twelve months to September 30, 2026 it reported net income of $116.8M on revenue of $1B, a net margin of 11.2%.

How much revenue does Ani Pharmaceuticals Inc make?

Over the twelve months to September 30, 2026 Ani Pharmaceuticals Inc reported revenue of $1B. That is 25.9% more than a year earlier.

When did Ani Pharmaceuticals Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.

When is Ani Pharmaceuticals Inc's next earnings report?

Ani Pharmaceuticals Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

TRAX

First Tracks Biotherapeutics, Inc.

XERS

Xeris Biopharma Holdings, Inc.

TYRA

Tyra Biosciences, Inc.

INVA

Innoviva, Inc.

JBIO

Jade Biosciences, Inc.

LBRX

LB Pharmaceuticals Inc

Compare ANIP with

Compare ANIP with any company

Follow ANIP

Get an email when Ani Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Ani Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.